Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. reports news on its dermatology therapeutics business, including commercialization of YCANTH (VP-102) for molluscum contagiosum and development of cantharidin-based therapy for common warts. Company updates also cover financial results, corporate presentations, commercial leadership and international commercialization activity.
Verrica’s pipeline news centers on VP-315 (ruxotemitide), an oncolytic peptide licensed for dermatologic oncology indications. Recurring disclosures include clinical data presentations in basal cell carcinoma, development plans for non-melanoma skin cancers and collaboration activity tied to YCANTH and its dermatology portfolio.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced acceptance of a late-breaking abstract reporting Phase 2 exploratory data for VP-315, its oncolytic peptide for basal cell carcinoma, showing a potential abscopal effect in untreated non-target BCC tumors.
The data will be presented at the 2026 Society for Investigative Dermatology Annual Meeting, May 13-16, with the poster session on May 15, 2026 (4:30 pm–6:00 pm) in Chicago (Hilton Chicago, Salons B,C,D).
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that President and CEO Jayson Rieger, PhD, MBA, will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 3:00pm ET.
A live webcast will be available via Verrica's investor site and a replay will be posted and available for 90 days.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported full-year 2025 results and operational updates on March 11, 2026. YCANTH net revenue grew 130% to $15.3M and dispensed applicator units rose 99% to 51,296. Total 2025 revenue was $35.6M vs. $7.6M in 2024.
The company cut SG&A by over 40%, has no outstanding debt after a $50M private placement, and expects cash runway into Q1 2027. Clinical progress: first patient dosed in Phase 3 common warts program and VP-315 advances toward Phase 3 for basal cell carcinoma with supportive abscopal data.
Verrica Pharmaceuticals (Nasdaq: VRCA) will report fourth quarter and full year 2025 financial results and provide a corporate update on March 11, 2026.
The company will host a conference call and live webcast at 8:30 a.m. ET; dial-in details, conference ID VERRICA, and a 90-day webcast replay are available on the company website.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that CEO Jayson Rieger will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 2, 2026 at 10:30am ET.
According to the company, a live webcast will be available on Verrica's investor website and a replay will be posted and available for 90 days.
Verrica Pharmaceuticals (Nasdaq: VRCA) appointed Chris Chapman as Chief Commercial Officer effective Feb 12, 2026. Chapman brings over 25 years of commercial pharmaceutical experience and leadership across dermatology, including roles at Dermavant, Organon, Galderma, and Pfizer.
Management expects Chapman to expand U.S. commercial capabilities for YCANTH, support the global Phase 3 program for common warts, and advance development of VP-315 for basal cell carcinoma.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced the launch of YCANTH in Japan by partner Torii Pharmaceutical for the treatment of molluscum contagiosum. YCANTH received MHLW approval based on positive Phase 3 topline results showing statistically significant complete clearance versus placebo.
Verrica retains global rights outside Japan; a multi‑year manufacturing transfer to Torii is planned, with interim transfer pricing and future royalties tied to transferred components and Torii net sales.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced the first patient was dosed in December 2025 in its global Phase 3 program evaluating YCANTH (VP-102) for common warts.
The Phase 3 start follows positive Phase 2 COVE-1 topline results where 51% (18 of 35) of subjects in Cohort 2 achieved complete clearance at Day 84; adverse events were primarily local cutaneous reactions with no SAEs observed. Verrica retains global rights to YCANTH outside Japan.
Torii will split Phase 3 costs 50/50, funding the first $40 million (about 90% of the current trial budget); Verrica recently completed a $50 million financing and repaid its OrbiMed debt facility. Verrica cites a U.S. prevalence of ~22 million patients and no FDA‑approved therapies for common warts.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced a private placement PIPE financing raising approximately $50 million in gross proceeds, expected to close on or about November 25, 2025. Verrica said it will use about $35.0 million of net proceeds to fully repay its credit agreement with OrbiMed and the remainder for working capital, extending its expected cash runway into mid-2027.
The financing is anchored by Caligan Partners and PBM Capital, includes sales of common stock, pre-funded warrants and accompanying Series C warrants, and gives Caligan the right to designate a board member.
Verrica Pharmaceuticals (Nasdaq: VRCA) reported $14.3M revenue in Q3 2025, driven by $3.6M YCANTH product sales and $10.7M license/collaboration revenue (including a $10M Torii milestone for Japan approval).
The company said dispensed YCANTH applicators rose to 37,642 YTD (a 120% increase vs prior year) and Q3 dispensings were 14,093 (+4.9% sequential). FDA and EMA provided positive regulatory feedback for VP-315 Phase 3 and YCANTH MAA pathways; Torii will fund most global Phase 3 wart trial costs. Q3 net loss was $0.3M and cash totaled $21.1M as of September 30, 2025.